Search Results - "LeTreut, J"

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study) by Raynaud, C, Greillier, L, Mazieres, J, Monnet, I, Mastroianni, B, Robinet, G, Fraboulet, G, Dixmier, A, Berard, H, Lamy, R, Letreut, J, Lena, H, Oliviero, G, Botta, S, Vergnenegre, A, Borget, I, Chouaid, C

“…Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens…”
Get full text

An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study by LeCaer, H, Fournel, P, Jullian, H, Chouaid, C, LeTreut, J, Thomas, P, Paillotin, D, Perol, M, Gimenez, C, Vergnenegre, A

“…Abstract The aim of this study was to determine the impact of patient selection based on age, comorbidity and performance status on the efficacy of…”
Get full text

Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer : A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie (GFPC) by VERGNENEGRE, A, DANIEL, C, PREUX, P. M, ROBINET, G, LENA, H, FOURNEL, P, KLEISBAUER, J. P, LE CAER, H, LETREUT, J, PAILLOTIN, D, PEROL, M, BOUCHAERT, E

“…The most satisfactory treatment for patients with locally advanced non-small-cell lung cancer (NSCLC) is combination chemotherapy-radiotherapy (CT-RT). The…”
Get full text

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies††These studies have previously been presented in part at the ASCO 2013 Annual Meeting, the ESMO-ECCO 2013 Annual Meeting and the IASLC 2013 World Conference on Lung Cancer by Moran, T., Wei, J., Qian, X., Domine, M., Zou, Z., Wang, L., Provencio, M., Yu, L., Song, Y., Vergnenegre, A., Lu, H., Lopez-Vivanco, G., Majem, M., Chen, X., Karachaliou, N., Sala, M.A., Wu, Q., Isla, D., Baize, N., Zhang, F., Garde, J., Germonpre, P., Drozdowskyj, A., Sanchez, J.J., Liu, B., Rosell, R., De Grève, J., Germonpré, P., Chen, H., Chen, X., Gao, Y., Hu, W., Kong, W., Li, L., Li, X., Lu, H., Qian, X., Ren, W., Song, Y., Wei, J., Xu, X., Yang, J., Yang, M., Yue, X., Zhang, J., Zou, Z., Bombaron, P., Dansin, E., Fraboulet, G., Hominal, S., Kahlout, S., Lecaer, H., Lena, H., Monnet, I., Oliviero, G., Schoot, R., Vergnènegre, A., Berchem, G., Al Husaini, H., Aparisi, F., Arriola, E., Bernabé, R., Bosch-Barrera, J., Bover, I., Calvo de Juan, V., Cobo, M., De las Peñas, R., García-Girón, C., García-Gómez, R., Garcia-Sevila, R., Garde, J., Gasco, A., González-Larriba, J.L., Hernando-Polo, S., Jantus, E., Isla, D., Jiménez, B., Lianes, P., López-Martín, A., Macias, J.A., Marti-Ciriquian, J.L., Morán, T., Moreno, M.A., Pallares, C., Porta, R., Reguart, N., Rosell, R., Rosillo, F., Sala, M.A., Sanchez, J.M., Trigo, J.M., Viteri, S., Mate, J.L., Perez-Cano, M., Ramirez, J.L., Sanchez-Rodriguez, B., Ocaña, J., Pereira, E., Shao, J., Sun, X.

“…In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly…”
Get full text

Randomized trial of adjuvant chemotherapy (Cx) with cisplatin plus gemcitabine (CG) versus cisplatin plus docetaxel (CD) in patients (pts) with completely resected non-small cell lung cancer (NSCLC) with quality of life (QoL) as the primary objective by Barlesi, F., Chouaid, C., Crequit, J., Lecaer, H., Pujol, J., Bérard, H., Vergnenegre, A., Letreut, J., Fabre-Guillevin, E., Loundou, A.

“…Abstract only 7532 Background: Adjuvant Cx with vinorelbine plus cisplatin (VC) improves survival of resected NSCLC but has an immediate negative impact on QoL…”
Get full text

Évaluation multicentrique et randomisée de l’impact des conseillers en environnement intérieur sur le contrôle de l’asthme : l’étude ECENVIR by Gangneux, J.P., Morel, H., Blanc, F.X., Bonniaud, P., Boza, G., Briault, A., Brouard, J., Charpin, D., Chenivesse, C., Colas, H., Cottereau, A., Dalampira, G., De Blay, F., Debeillex, X., Dumont, P., Elchehaded, K., Fayon, M., Fry, S., Hullo, E., Leblanc, A., Letreut, J., Magnan, A., Mahay, G., Perotin-Collard, J.M., Pegliasco, H., Pin, I., Pison, C., Rossignoli, N., Siao Him Fa, V., Ziani Bey, H., Com-Ruelle, L., Morcet, J., Oger, E., Le Cann, P.

“…L’exposition répétée des patients asthmatiques aux allergènes intradomiciliaires contribue aux exacerbations de l’asthme. Plusieurs stratégies d’intervention…”
Get full text

O-091 A randomized phase II trial of docetaxel alone and in combinationwith gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer by Robinet, G., Falchero, L., Perol, M., Thomas, P., Monnet, I., Grivaux, M., Crequit, J., Letreut, J., Paillotin, D., Chouaid, C.

Get full text

Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer by Vergnenègre, A., Daniel, C., Léna, H., Fournel, P., Kleisbauer, J.P., Caer, H. Le, Letreut, J., Paillotin, D., Pérol, M., Bouchaert, E., Preux, P.M., Robinet, G.

“…The most satisfactory treatment for patients with locally advanced non-small-cell lung cancer (NSCLC) is combination chemotherapy–radiotherapy (CT–RT). The…”
Get full text